A meta-analysis evaluating indirectly GLP-1 receptor agonists and arrhythmias in patients with type 2 diabetes and myocardial infarction
AimsAt present, the effects of Glucagon-Like Peptide 1 Receptor agonists (GLP-1RAs) on arrhythmia in patients with type 2 diabetes mellitus (T2DM) and myocardial infarction (MI) are still unclear. Hence, this systematic review and meta-analysis aimed to investigate this association.Methods and resul...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-10-01
|
| Series: | Frontiers in Cardiovascular Medicine |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fcvm.2022.1019120/full |
| _version_ | 1828727663344222208 |
|---|---|
| author | Zhijie Liu Ning Bian Shaorong Wu Yiming Fan Hairui Li Jian Yu Jun Guo Dongdong Chen |
| author_facet | Zhijie Liu Ning Bian Shaorong Wu Yiming Fan Hairui Li Jian Yu Jun Guo Dongdong Chen |
| author_sort | Zhijie Liu |
| collection | DOAJ |
| description | AimsAt present, the effects of Glucagon-Like Peptide 1 Receptor agonists (GLP-1RAs) on arrhythmia in patients with type 2 diabetes mellitus (T2DM) and myocardial infarction (MI) are still unclear. Hence, this systematic review and meta-analysis aimed to investigate this association.Methods and resultsPubMed, Embase, Cochrane Library, and Web of Science were searched from inception to 30 April 2022. Randomized controlled trials (RCTs) that compared GLP-1RAs with placebo and met the critical criterion of a proportion of patients with T2DM and MI > 30% were included to verify our purpose indirectly. The outcomes of interest included atrial arrhythmias, ventricular arrhythmias, atrioventricular block (AVB), sinus arrhythmia, and cardiac arrest. Relative risk (RR) and 95% confidence intervals (CI) were pooled using a random-effects model. We included five RCTs with altogether 31,314 patients. In these trials, the highest proportion of patients with T2DM and MI was 82.6%, while the lowest was 30.7%. Compared to placebo, GLP-1RAs were associated with a lower risk of atrial arrhythmias (RR 0.81, 95% CI 0.70–0.95). There was no significant difference in the risk of ventricular arrhythmias (RR 1.26, 95% CI 0.87–1.80), AVB (RR 0.95, 95% CI 0.63–1.42), sinus arrhythmia (RR 0.62, 95% CI 0.26–1.49), and cardiac arrest (RR 0.97, 95% CI 0.52–1.83) between groups.ConclusionGLP-1RAs may be associated with reduced risk for atrial arrhythmias, which seems more significant for patients with T2DM combined with MI. More studies are needed to clarify the definitive anti-arrhythmic role of this drug. |
| first_indexed | 2024-04-12T14:01:37Z |
| format | Article |
| id | doaj.art-0465ab936c284e2d92c762bb007e8ed1 |
| institution | Directory Open Access Journal |
| issn | 2297-055X |
| language | English |
| last_indexed | 2024-04-12T14:01:37Z |
| publishDate | 2022-10-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Cardiovascular Medicine |
| spelling | doaj.art-0465ab936c284e2d92c762bb007e8ed12022-12-22T03:30:11ZengFrontiers Media S.A.Frontiers in Cardiovascular Medicine2297-055X2022-10-01910.3389/fcvm.2022.10191201019120A meta-analysis evaluating indirectly GLP-1 receptor agonists and arrhythmias in patients with type 2 diabetes and myocardial infarctionZhijie LiuNing BianShaorong WuYiming FanHairui LiJian YuJun GuoDongdong ChenAimsAt present, the effects of Glucagon-Like Peptide 1 Receptor agonists (GLP-1RAs) on arrhythmia in patients with type 2 diabetes mellitus (T2DM) and myocardial infarction (MI) are still unclear. Hence, this systematic review and meta-analysis aimed to investigate this association.Methods and resultsPubMed, Embase, Cochrane Library, and Web of Science were searched from inception to 30 April 2022. Randomized controlled trials (RCTs) that compared GLP-1RAs with placebo and met the critical criterion of a proportion of patients with T2DM and MI > 30% were included to verify our purpose indirectly. The outcomes of interest included atrial arrhythmias, ventricular arrhythmias, atrioventricular block (AVB), sinus arrhythmia, and cardiac arrest. Relative risk (RR) and 95% confidence intervals (CI) were pooled using a random-effects model. We included five RCTs with altogether 31,314 patients. In these trials, the highest proportion of patients with T2DM and MI was 82.6%, while the lowest was 30.7%. Compared to placebo, GLP-1RAs were associated with a lower risk of atrial arrhythmias (RR 0.81, 95% CI 0.70–0.95). There was no significant difference in the risk of ventricular arrhythmias (RR 1.26, 95% CI 0.87–1.80), AVB (RR 0.95, 95% CI 0.63–1.42), sinus arrhythmia (RR 0.62, 95% CI 0.26–1.49), and cardiac arrest (RR 0.97, 95% CI 0.52–1.83) between groups.ConclusionGLP-1RAs may be associated with reduced risk for atrial arrhythmias, which seems more significant for patients with T2DM combined with MI. More studies are needed to clarify the definitive anti-arrhythmic role of this drug.https://www.frontiersin.org/articles/10.3389/fcvm.2022.1019120/fullGlucagon-Like Peptide 1 Receptor agonistsGLP-1RAsarrhythmiatype 2 diabetes mellitusmyocardial infarction |
| spellingShingle | Zhijie Liu Ning Bian Shaorong Wu Yiming Fan Hairui Li Jian Yu Jun Guo Dongdong Chen A meta-analysis evaluating indirectly GLP-1 receptor agonists and arrhythmias in patients with type 2 diabetes and myocardial infarction Frontiers in Cardiovascular Medicine Glucagon-Like Peptide 1 Receptor agonists GLP-1RAs arrhythmia type 2 diabetes mellitus myocardial infarction |
| title | A meta-analysis evaluating indirectly GLP-1 receptor agonists and arrhythmias in patients with type 2 diabetes and myocardial infarction |
| title_full | A meta-analysis evaluating indirectly GLP-1 receptor agonists and arrhythmias in patients with type 2 diabetes and myocardial infarction |
| title_fullStr | A meta-analysis evaluating indirectly GLP-1 receptor agonists and arrhythmias in patients with type 2 diabetes and myocardial infarction |
| title_full_unstemmed | A meta-analysis evaluating indirectly GLP-1 receptor agonists and arrhythmias in patients with type 2 diabetes and myocardial infarction |
| title_short | A meta-analysis evaluating indirectly GLP-1 receptor agonists and arrhythmias in patients with type 2 diabetes and myocardial infarction |
| title_sort | meta analysis evaluating indirectly glp 1 receptor agonists and arrhythmias in patients with type 2 diabetes and myocardial infarction |
| topic | Glucagon-Like Peptide 1 Receptor agonists GLP-1RAs arrhythmia type 2 diabetes mellitus myocardial infarction |
| url | https://www.frontiersin.org/articles/10.3389/fcvm.2022.1019120/full |
| work_keys_str_mv | AT zhijieliu ametaanalysisevaluatingindirectlyglp1receptoragonistsandarrhythmiasinpatientswithtype2diabetesandmyocardialinfarction AT ningbian ametaanalysisevaluatingindirectlyglp1receptoragonistsandarrhythmiasinpatientswithtype2diabetesandmyocardialinfarction AT shaorongwu ametaanalysisevaluatingindirectlyglp1receptoragonistsandarrhythmiasinpatientswithtype2diabetesandmyocardialinfarction AT yimingfan ametaanalysisevaluatingindirectlyglp1receptoragonistsandarrhythmiasinpatientswithtype2diabetesandmyocardialinfarction AT hairuili ametaanalysisevaluatingindirectlyglp1receptoragonistsandarrhythmiasinpatientswithtype2diabetesandmyocardialinfarction AT jianyu ametaanalysisevaluatingindirectlyglp1receptoragonistsandarrhythmiasinpatientswithtype2diabetesandmyocardialinfarction AT junguo ametaanalysisevaluatingindirectlyglp1receptoragonistsandarrhythmiasinpatientswithtype2diabetesandmyocardialinfarction AT dongdongchen ametaanalysisevaluatingindirectlyglp1receptoragonistsandarrhythmiasinpatientswithtype2diabetesandmyocardialinfarction AT zhijieliu metaanalysisevaluatingindirectlyglp1receptoragonistsandarrhythmiasinpatientswithtype2diabetesandmyocardialinfarction AT ningbian metaanalysisevaluatingindirectlyglp1receptoragonistsandarrhythmiasinpatientswithtype2diabetesandmyocardialinfarction AT shaorongwu metaanalysisevaluatingindirectlyglp1receptoragonistsandarrhythmiasinpatientswithtype2diabetesandmyocardialinfarction AT yimingfan metaanalysisevaluatingindirectlyglp1receptoragonistsandarrhythmiasinpatientswithtype2diabetesandmyocardialinfarction AT hairuili metaanalysisevaluatingindirectlyglp1receptoragonistsandarrhythmiasinpatientswithtype2diabetesandmyocardialinfarction AT jianyu metaanalysisevaluatingindirectlyglp1receptoragonistsandarrhythmiasinpatientswithtype2diabetesandmyocardialinfarction AT junguo metaanalysisevaluatingindirectlyglp1receptoragonistsandarrhythmiasinpatientswithtype2diabetesandmyocardialinfarction AT dongdongchen metaanalysisevaluatingindirectlyglp1receptoragonistsandarrhythmiasinpatientswithtype2diabetesandmyocardialinfarction |